Search Results 471-480 of 14951 for alt

1. Losartan for Outpatients on COVID-19 - Clinical Trials

   Documented AST or ALT > 3 times the upper limit of normal within 3 months of randomization (if available in electronic medical record). Potassium > 5.0 mmol ...

2. Clinical Trials - FT576 in Subjects With Multiple Myeloma

   - AST > 3 x ULN or ALT > 3 x ULN, unless directly due to underlying malignancy. - O2 sat < 92% on room air. Clinically significant cardiovascular disease ...

3. Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy - Mayo Clinic

   Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) ≤ 2.5x ULN; Alkaline Phosphatase <5x ULN. All females of childbearing potential (not ...

4. A Study Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma - Mayo Clinic

   AST/ALT ≤ 3.0 x ULN;; Creatinine < 1.5 x ULN OR Calc. Creatinine Clearance > 50 mL/min.***. *. In the absence of transfusion within the previous 24 hours ...

5. Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma - Mayo Clinic

   Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN. Calculated creatinine clearance (CrCL) ≥ 30 mL/min. Eastern Cooperative ...

6. A Study to Evaluate the Combination of Binimetinib and Palbociclib in Treating Patients with KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer - Mayo Clinic

   Aspartate transaminase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN; ≤ 5.0 x ULN if known liver metastases;; Serum creatinine ≤ 1.5 mg/dL OR ...

7. Study to Analyze Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy - Mayo Clinic

   AST or ALT ≤ 3 x upper limit of normal (ULN). Exclusion Criteria: Any non-compliance with Inclusion Criteria above. Participating Mayo Clinic locations.

8. Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma - Mayo Clinic

   Hepatic function: Conjugated bilirubin <1.5 × ULN and ALT and AST <3 × ULN. Has a QT interval corrected by Fridericia's formula (QTcF) ≤480 msec; Willing to ...

9. Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

   Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and ... For subjects with HCC: ALT, AST, and ALP ≤ 5 × ULN. For subjects with mCRPC ...

10. A Study to Evaluate Exemestane in Post-Menopausal Women with Non-Small Cell Lung Cancer (NSCLC) - Mayo Clinic

    AST/SGOT and ALT/SGPT ≤ 2.5 x upper limit of normal (ULN), except if there is known hepatic metastasis, wherein transaminases may be ≤ 5 x institutional ULN.